Botulinum toxin type A in chronic neuropathic pain in refractory leprosy
ABSTRACT Neuropathic pain is a chronic syndrome that is difficult to treat and often affects patients with leprosy. Recommended treatment includes the the use of analgesic drugs, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide, but without consensus on uniform dose...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academia Brasileira de Neurologia (ABNEURO)
|
| Series: | Arquivos de Neuro-Psiquiatria |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000500346&lng=en&tlng=en |
| _version_ | 1818129113846644736 |
|---|---|
| author | Emanuel de Jesus Soares de Sousa Gustavo Celeira de Sousa Vitor Ferreira Baia Danusa Neves Somensi Marília Brasil Xavier |
| author_facet | Emanuel de Jesus Soares de Sousa Gustavo Celeira de Sousa Vitor Ferreira Baia Danusa Neves Somensi Marília Brasil Xavier |
| author_sort | Emanuel de Jesus Soares de Sousa |
| collection | DOAJ |
| description | ABSTRACT Neuropathic pain is a chronic syndrome that is difficult to treat and often affects patients with leprosy. Recommended treatment includes the the use of analgesic drugs, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide, but without consensus on uniform dose and fully satisfactory results. Objective: To analyze botulinum toxin type A (BoNT-A) effectiveness in treatment of chronic neuropathic pain in refractory leprous patients, as well as evaluate and compare the quality of life of patients before and after using the medication. Methods: We used a specific protocol including clinical, demographic, DN4 protocol, analogue scale (VAS), sensory evaluation and evaluation of the WHOQOL-BREF. Therapeutic intervention was performed with BOTOX® BTX-A 100U administered subcutaneously. Fifteen patients were evaluated on days 0, 10 and 60. Results: Patients on VAS showed pain between 5 and 10, in one case there was complete pain relief in 60 days, while others showed improvement in the first week with the return of symptoms with less intensity after this period. WHOQOL-BREF's domains Quality of Life and Physical to have a significant increase in QOL. Conclusion: BoNT-A proved to be a good therapeutic option in relieving pain with improved quality of life for these patients. |
| first_indexed | 2024-12-11T07:43:59Z |
| format | Article |
| id | doaj.art-7af96e2b67d34049b3dfca1016f0c7dc |
| institution | Directory Open Access Journal |
| issn | 1678-4227 |
| language | English |
| last_indexed | 2024-12-11T07:43:59Z |
| publisher | Academia Brasileira de Neurologia (ABNEURO) |
| record_format | Article |
| series | Arquivos de Neuro-Psiquiatria |
| spelling | doaj.art-7af96e2b67d34049b3dfca1016f0c7dc2022-12-22T01:15:30ZengAcademia Brasileira de Neurologia (ABNEURO)Arquivos de Neuro-Psiquiatria1678-422777534635110.1590/0004-282x20190053S0004-282X2019000500346Botulinum toxin type A in chronic neuropathic pain in refractory leprosyEmanuel de Jesus Soares de SousaGustavo Celeira de SousaVitor Ferreira BaiaDanusa Neves SomensiMarília Brasil XavierABSTRACT Neuropathic pain is a chronic syndrome that is difficult to treat and often affects patients with leprosy. Recommended treatment includes the the use of analgesic drugs, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide, but without consensus on uniform dose and fully satisfactory results. Objective: To analyze botulinum toxin type A (BoNT-A) effectiveness in treatment of chronic neuropathic pain in refractory leprous patients, as well as evaluate and compare the quality of life of patients before and after using the medication. Methods: We used a specific protocol including clinical, demographic, DN4 protocol, analogue scale (VAS), sensory evaluation and evaluation of the WHOQOL-BREF. Therapeutic intervention was performed with BOTOX® BTX-A 100U administered subcutaneously. Fifteen patients were evaluated on days 0, 10 and 60. Results: Patients on VAS showed pain between 5 and 10, in one case there was complete pain relief in 60 days, while others showed improvement in the first week with the return of symptoms with less intensity after this period. WHOQOL-BREF's domains Quality of Life and Physical to have a significant increase in QOL. Conclusion: BoNT-A proved to be a good therapeutic option in relieving pain with improved quality of life for these patients.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000500346&lng=en&tlng=enLeprosybotulinum toxins |
| spellingShingle | Emanuel de Jesus Soares de Sousa Gustavo Celeira de Sousa Vitor Ferreira Baia Danusa Neves Somensi Marília Brasil Xavier Botulinum toxin type A in chronic neuropathic pain in refractory leprosy Arquivos de Neuro-Psiquiatria Leprosy botulinum toxins |
| title | Botulinum toxin type A in chronic neuropathic pain in refractory leprosy |
| title_full | Botulinum toxin type A in chronic neuropathic pain in refractory leprosy |
| title_fullStr | Botulinum toxin type A in chronic neuropathic pain in refractory leprosy |
| title_full_unstemmed | Botulinum toxin type A in chronic neuropathic pain in refractory leprosy |
| title_short | Botulinum toxin type A in chronic neuropathic pain in refractory leprosy |
| title_sort | botulinum toxin type a in chronic neuropathic pain in refractory leprosy |
| topic | Leprosy botulinum toxins |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2019000500346&lng=en&tlng=en |
| work_keys_str_mv | AT emanueldejesussoaresdesousa botulinumtoxintypeainchronicneuropathicpaininrefractoryleprosy AT gustavoceleiradesousa botulinumtoxintypeainchronicneuropathicpaininrefractoryleprosy AT vitorferreirabaia botulinumtoxintypeainchronicneuropathicpaininrefractoryleprosy AT danusanevessomensi botulinumtoxintypeainchronicneuropathicpaininrefractoryleprosy AT mariliabrasilxavier botulinumtoxintypeainchronicneuropathicpaininrefractoryleprosy |